Primary Immunodeficiencies in Costa Rican Adults

NCT04963660 | Completed

• 1 other identifier: R017-SABI-00148.
• Study Type: observational
• Target: 137
• Locations: 1 country
• Sites: 1

Brief Summary

Primary immunodeficiencies represent a underdiagnosed group of rare diseases which if diagnosed well and in time can be treated in an efficient manner and prevent complications that may affect the quality of patients life in an severe manner. Neither in Costa Rica nor in Central America studies or national registries regarding the prevalence and characterization of primary immunodeficiencies in adult patients exist up to now. This study reflects for the first time the epidemiologic situation of primary immunodeficiencies in a Central American country, characterizing adult patients diagnosed with primary and idiopathic immune disorders treated in two specialized immunodeficiency clinics in Costa Rica.

Conditions

Primary Immune Deficiency in Adults

Outcome Measures

Primary Outcomes (1)

• Clinical manifestations of all adult patients diagnosed with primary and idiopathic immune defects

  Describe the clinical manifestations of all adult patients diagnosed with primary and idiopathic immune defects attended in the primary immunodeficiency clinics of the Hospitals Mexico and Dr. Rafael Ángel Calderón Guardia during the study period.

  1 year

Secondary Outcomes (6)

• characterization of immunodeficient patients

  1 year

• Concordances between clinical manifestations and literature

  1 year

• organic complications

  1 year

• type and degree of immunodeficiency

  1 year

• pathonges that cause infectious

  1 year

Eligibility Criteria

• Age: 12 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All cases of primary immunodeficiency and idiopathic defects of immunity detected in the primary immunodeficiency clinics of the Hospitals Mexico and Dr. Rafael Ángel Calderón Guardia between November 2017 and May 2018.

You may qualify if:

• All patients from adult primary immunodeficiency clinics will be included.

You may not qualify if:

• Patients with HIV
• Proven secondary immunodeficiencies.

Sponsors & Collaborators

• Caja Costarricense de Seguro Social: lead

Study Sites (1)

Hospital Calderon Guardia

San José, 00000, Costa Rica

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Year
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 6, 2021
• First Posted: July 15, 2021
• Study Start: November 11, 2018
• Primary Completion: November 11, 2019
• Study Completion: November 11, 2019
• Last Updated: July 15, 2021

Record last verified: 2021-07

Locations

CO (1)